 |
ZAMBART Project is a public health research non-governmental organization conducting scientific research into the dual epidemics of tuberculosis and HIV. The organization is based in Lusaka, Zambia at the University of Zambia's School of Medicine Ridgeway Campus. ZAMBART has over 200 employees and works in 16 study sites throughout the country.
The Zambia AIDS Related Tuberculosis (ZAMBART) Project is a Zambian NGO formed in 2004 from a collaboration between the University of Zambia’s School of Medicine and the London School of Hygiene and Tropical Medicine that spans more than 20 years. From the initial studies of the impact of HIV on the clinical presentation and outcome of tuberculosis, the scope and partnership of the research have expanded widely. Based in Lusaka, ZAMBART now collaborates closely with government, non-governmental and academic institutions within Zambia, Africa and the rest of the world. ZAMBART staff form an interdisciplinary team with a range of expertise including epidemiology, clinical science, social science, laboratory, operations research, health systems and services research, health policy analysis, health economics, development communication and counselling.
ZAMBART focuses on the overlap between HIV and TB in order to improve the quality of life of people affected by the dual epidemic. Conducting research within a limited resource setting, ZAMBART is committed to: bridging research and action through operational research and through forging effective collaboration with local stakeholders; providing evidence-based and high quality research; addressing relevant scientific and priority questions; and capacity building for Zambian research - both scientific and managerial.
Internationally, ZAMBART is recognised as one of the foremost TB/HIV research groups in the world. Representatives sit on the World Health Organization (WHO) TB/HIV working group and have assisted in the writing of WHO technical guidelines and policy documents. In addition, ZAMBART is actively involved in regional and international research consortia through TARGETS, Evidence for Action and the Consortium to Respond Effectively to the AIDS/TB Epidemic (CREATE).
ZAMBART has no core funding but has been successful in attracting grants from a wide range of sources. Much of the current portfolio of activity is funded through the Department For International Development (DFID) Knowledge Programmes on Tuberculosis (TARGETS) and HIV (Evidence for Action) and the CREATE Consortium, funded by the Bill and Melinda Gates Foundation.
The World Health Organization (WHO) is a specialized agency of the United Nations responsible for international public health. Headquartered in Geneva, Switzerland, it has six regional offices and 150 field offices worldwide.
The United States President's Emergency Plan For AIDS Relief (PEPFAR) is a United States governmental initiative to address the global HIV/AIDS epidemic and help save the lives of those suffering from the disease. Launched by U.S. President George W. Bush in 2003, as of May 2020, PEPFAR has provided about $90 billion in cumulative funding for HIV/AIDS treatment, prevention, and research since its inception, making it the largest global health program focused on a single disease in history until the COVID-19 pandemic. PEPFAR is implemented by a combination of U.S. government agencies in over 50 countries and overseen by the Global AIDS Coordinator at the United States Department of State. As of 2021, PEPFAR has saved over 20 million lives, primarily in Sub-Saharan Africa.
Partners In Health (PIH) is an international nonprofit public health organization founded in 1987 by Paul Farmer, Ophelia Dahl, Thomas J. White, Todd McCormack, and Jim Yong Kim.
The AIDS Clinical Trials Group network (ACTG) is one of the largest HIV clinical trials organizations in the world, playing a major role in setting standards of care for HIV infection and opportunistic diseases related to HIV and AIDS in the United States and the developing world. The ACTG is composed of, and directed by, leading clinical scientists in HIV/AIDS therapeutic research. The ACTG is funded by the Department of Health and Human Services, National Institutes of Health through the National Institute of Allergy and Infectious Diseases.
Tuberculosis is a serious public health problem in China. China has the world's third largest cases of tuberculosis, but progress in tuberculosis control was slow during the 1990s. Detection of tuberculosis had stagnated at around 30% of the estimated total of new cases, and multidrug-resistant tuberculosis was a major problem. These signs of inadequate tuberculosis control can be linked to a malfunctioning health system. The spread of severe acute respiratory syndrome (SARS) in 2003, brought to light substantial weaknesses in the country's public health system. After the government realized the impact that the SARS outbreak had on the country, they increased leadership in their health department. After the SARS epidemic was brought under control, the government increased its commitment and leadership to tackle public health problems and, among other efforts, increased public health funding, revised laws that concerned the control of infectious diseases, implemented the world's largest internet-based disease reporting system to improve transparency, reach and speed, and started a program to rebuild local public health facilities and national infrastructure.
The Centre for Infectious Disease Research in Zambia (CIDRZ) is a non-profit organisation founded in 2001 as collaboration between the University of Alabama at Birmingham, USA, the Ministry of Health of Zambia and the University of Zambia School of Medicine. In 2011 CIDRZ became an independent, Zambian, non-governmental organisation able to collaborate with multiple local and international universities.
Since the first HIV/AIDS case in the Lao People's Democratic Republic (PDR) was identified in 1990, the number of infections has continued to grow. In 2005, UNAIDS estimated that 3,700 people in Lao PDR were living with HIV.
With less than 0.1 percent of the population estimated to be HIV-positive, Bangladesh is a low HIV-prevalence country.
Since HIV/AIDS was first reported in Thailand in 1984, 1,115,415 adults had been infected as of 2008, with 585,830 having died since 1984. 532,522 Thais were living with HIV/AIDS in 2008. In 2009 the adult prevalence of HIV was 1.3%. As of 2016, Thailand had the highest prevalence of HIV in Southeast Asia at 1.1 percent, the 40th highest prevalence of 109 nations.
The Dominican Republic has a 0.7 percent prevalence rate of HIV/AIDS, among the lowest percentage-wise in the Caribbean region. However, it has the second most cases in the Caribbean region in total, with an estimated 46,000 HIV/AIDS-positive Dominicans as of 2013.
Global Health Initiatives (GHIs) are humanitarian initiatives that raise and disburse additional funds for infectious diseases – such as AIDS, tuberculosis, and malaria – for immunizations and for strengthening health systems in developing countries. GHIs classify a type of global initiative, which is defined as an organized effort integrating the involvement of organizations, individuals, and stakeholders around the world to address a global issue.
Sir Alimuddin Zumla,, FRCP, FRCPath, FRSB is a British-Zambian professor of infectious diseases and international health at University College London Medical School. He specialises in infectious and tropical diseases, clinical immunology, and internal medicine, with a special interest in HIV/AIDS, respiratory infections, and diseases of poverty. He is known for his leadership of infectious/tropical diseases research and capacity development activities. He was awarded a Knighthood in the 2017 Queens Birthday Honours list for services to public health and protection from infectious disease. In 2012, he was awarded Zambia's highest civilian honour, the Order of the Grand Commander of Distinguished services - First Division. In 2022, for the fifth consecutive year, Zumla was recognised by Clarivate Analytics, Web of Science as one of the world's top 1% most cited researchers. In 2021 Sir Zumla was elected as Fellow of The World Academy of Sciences.
Agnes Binagwaho is a Rwandan pediatrician and co-founder and the former vice chancellor of the University of Global Health Equity (2017-2022). In 1996, she returned to Rwanda where she provided clinical care in the public sector as well as held many positions including the position of Permanent Secretary for the Ministry of Health of Rwanda from October 2008 until May 2011 and Minister of Health from May 2011 until July 2016. She has been a Professor of Global Health Delivery Practice since 2016 and a Professor of Pediatrics since 2017 at the University of Global Health Equity. She resides in Kigali.
Tuberculosis in India is a major health problem, causing about 220,000 deaths every year. In 2020, the Indian government made statements to eliminate tuberculosis from the country by 2025 through its National TB Elimination Program. Interventions in this program include major investment in health care, providing supplemental nutrition credit through the Nikshay Poshan Yojana, organizing a national epidemiological survey for tuberculosis, and organizing a national campaign to tie together the Indian government and private health infrastructure for the goal of eliminating the disease.
The Medicines Patent Pool (MPP) is a Unitaid-backed international organisation founded in July 2010, based in Geneva, Switzerland. Its public health driven business model aims to lower the prices of HIV, tuberculosis and hepatitis C medicines and facilitate the development of better-adapted HIV treatments through voluntary licensing and patent pooling. Its goal is to improve access to affordable and appropriate HIV, hepatitis C and tuberculosis medicines in low- and middle-income countries (LMIC). In May 2020, the MPP become an implementing partner of the WHO's Covid-19 Technology Access Pool (C-TAP).
Salim S. Abdool Karim, MBChB, MMed, MS(Epi), FFPHM, FFPath (Virol), DipData, PhD, DSc(hc) is a South African public health physician, epidemiologist and virologist who has played a leading role in the AIDS and COVID-19 pandemic. His scientific contributions have impacted the landscape of HIV prevention and treatment, saving thousands of lives
The Health in Eswatini is poor and four years into the United Nations sustainable development goals, Eswatini seems unlikely to achieve goal on health. As a result of 63% poverty prevalence, 27% HIV prevalence, and poor health systems, maternal mortality rate is a high 389/100,000 live births, and under 5 mortality rate is 70.4/1000 live births resulting in a life expectancy that remains amongst the lowest in the world. Despite significant international aid, the government fails to adequately fund the health sector. Nurses are now and again engaged in demonstrations over poor working conditions, drug stock outs, all of which impairs quality health delivery. Despite tuberculosis and AIDS being major causes of death, diabetes and other non-communicable diseases are on the rise. Primary health care is relatively free in Eswatini save for its poor quality to meet the needs of the people. Road traffic accidents have increased over the years and they form a significant share of deaths in the country.
Alash'le Grace Abimiku is a Nigerian executive director of the International Research Centre of Excellence at the Institute of Human Virology Nigeria and a Professor of Virology at the University of Maryland School of Medicine.
Etienne Karita is a Rwandan scientist who has been researching HIV/AIDS in Rwanda since the mid-1980s. He has held numerous leadership positions in different organizations that are working to control HIV in Rwanda. Some of his work is concentrated on preventing mother to child transmission of HIV and in collaboration with Projet San Francisco, he has studied HIV in discordant couples.